长期使用曲安奈德治疗哮喘期间影响肾上腺皮质抑制的因素。
Factors influencing adrenocortical suppression during long-term triamcinolone acetonide therapy in asthma.
作者信息
Droszcz W, Lech B, Malunowicz E, Piotrowska B
出版信息
Ann Allergy. 1980 Mar;44(3):174-6.
The causes for an abnormal five-hour tetracosactrin test in 14 out of 75 patients (18.5% of the entire group), treated continuously with triamcinolone acetonide long-term (mean 3.2 years) for asthma or related syndromes, were investigated. The average daily dosage, duration of treatment and age of the patients were analyzed. Statistical analysis indicated that the risk of adrenocortical suppression was increased by the patient's age and the average patients under the age of 50, receiving less than 1.2 mg triamcinolone acetonide daily, only rarely develop adrenocortical functional impairment.
对75例长期（平均3.2年）连续使用曲安奈德治疗哮喘或相关综合征的患者进行调查，其中14例（占整个组的18.5%）促肾上腺皮质激素（二十四肽促皮质素）五小时试验结果异常。分析了患者的平均每日剂量、治疗持续时间和年龄。统计分析表明，肾上腺皮质抑制的风险因患者年龄而增加，50岁以下且每日接受曲安奈德少于1.2毫克的患者很少发生肾上腺皮质功能损害。
Zotero 插件